Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06300996 · ClinicalTrials.gov registry record · NA

Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb

A NA study of Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3, sponsored by Marco Capogrosso.

Active
Registry status
NA
Development phase
3
Enrollment target
1
Study location

NCT06300996: Active NA study of Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3, sponsored by Marco Capogrosso.

NCT06300996 is a NA study of Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3 that is active but no longer recruiting, run by Marco Capogrosso. The registered enrollment target is 3 participants, below the 109-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06300996, a NA study of Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3, is active but no longer recruiting, sponsored by Marco Capogrosso.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with Type 2, 3, or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 2, 3, or 4 SMA aged 16 or older that show quantifiable motor deficits of the upper body. The investigators will then implant the subjects with percutaneous, linear spinal leads near the cervical spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.

Primary Outcome

Isometric torque: measure the isometric torque produced by the subject at the elbow during flexion. The investigators will use the measurement of isometric torque to determine the changes in muscle strength for each participant with SCS on and with SCS off. This comparison will also include testing the non-affected arm to give the investigators a baseline for normal movement of the joint being tested. Success Criteria: ≥30% increased torque production over the SCS-off/non-affected baseline as me

Conditions Studied

Spinal Muscular Atrophy Spinal Muscular Atrophy Type 3 SMA Spinal Muscular Atrophy Type II Spinal Muscular Atrophy 4

Interventions

  • DEVICE Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2024-05-31
Est. Completion 2029-09
Phase NA
Marco Capogrosso

3 total trials

What the registry record for NCT06300996 still lists

NCT06300996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 109-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (97% lower).

The record links to 5 conditions, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) is the first listed.

NCT06300996 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06300996 about?

NCT06300996 is a clinical study titled "Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb". Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor d...

What is the current status of trial NCT06300996?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 3 participants. The study started on 2024-05-31. Estimated completion is 2029-09.

What conditions does trial NCT06300996 study?

This clinical trial studies the following conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, SMA, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy 4.

What interventions are being tested in trial NCT06300996?

The interventions under investigation include: Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) (DEVICE).

Who is sponsoring clinical trial NCT06300996?

This trial is sponsored by Marco Capogrosso, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06300996 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Muscular Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06300996's enrollment target sits among peer trials

3 23rd of 22 the lowest of 22 other Spinal Muscular Atrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Muscular Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06300996, the US trial registry maintained by the National Library of Medicine. NCT06300996 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.